associated with a profound negative effect on quality of life. 3 Approximately 8%-20% of patients with MF eventually transform into acute myeloid leukaemia and consequently have an even shorter survival. [4] [5] [6] Historically, available treatment options for MF have been symptomatic with limited or no disease modifying potential. In a Swedish population-based study, Hultkrantz et al 2 described improved survival outcomes in MPN patients over the last decades; however, the improvement was less pronounced after the calendar year 2000 and confined to patients with PV and ET, suggesting dismal outcomes with current treatment options for MF in clinical practice. Recent evidence suggests that the Janus kinase (JAK) signalling pathway may play a central role in the pathogenesis of MF. Results from clinical studies suggest that the JAK-1/2 inhibitor ruxolitinib is effective in reducing symptoms of MF, which also has translated into improved quality of life. 1 Ruxolitinib was approved based on the results of two phase-III studies that compared ruxolitinib with placebo or best available care. The US Food and Drug Administration approved ruxolitinib for intermediate and high-risk MF, 7, 8 while the European Medicines Agency approved ruxolitinib for treatment of splenomegaly and/or constitutional symptoms of MF, irrespective of risk group. 1 There is limited evidence to show that ruxolitinib improves survival outcomes by modifying the disease course, although its effect on metabolic and nutritional variables may translate into survival benefits. 9 Eventually, most patients discontinue treatment due to adverse events or lack of efficacy. 9 In recent phase-III studies, about 50% of patients discontinued ruxolitinib within 3 years of treatment. 7 Salvage therapy options remain scarce 10 and mostly include allogeneic stem cell transplantation (allo-SCT) followed by immunomodulators; however, prognosis is unfavourable. 9 Although allo-SCT is the only curative treatment, it is rarely used in Sweden and Norway in this patient population due to the significant risk of morbidity and mortality. 11 Randomised controlled clinical trials are critical tools when assessing benefits of novel agents compared to standard of care.
However, longitudinal observational studies can be an invaluable complement to these studies in the evaluation of patient outcomes in clinical practice. The present study is the first national population-based study to describe survival outcomes in MF patients receiving ruxolitinib outside clinical trial settings in Sweden and Norway. For the present study, inclusion criteria were age ≥18 years at and 98% in Norway. 13 Although the Cancer Register has a high overall coverage, there has been a certain degree of under-reporting of indolent malignancies such as MPNs and Waldenström Macroglobulinemia. 14, 15 Mortality data were collected from the Cause of Death Registries (Sweden: January, 2014 to November, 2017; Norway: January, 2014 to September 2017).
| PATIENTS AND ME THODS

| Data sources and patient selection
The study was approved by the Regional Ethical Review Board in Stockholm and the SOR-OST Regional Ethics Committee in Norway.
The study was also approved by the National Board of Health and Welfare in Sweden, and the National Agency of Data Protection in Norway, for patient integrity and data handling. Informed consent was waived since there was no contact with study objectives.
| Study design and data collection
This was a retrospective cohort study. All patients who received ruxolitinib (n = 190) were followed from treatment initiation until death, 
| Statistical analysis
Overall survival (OS) and relative survival (RS) were estimated. For the RS analyses, excess mortality of MF patients compared with a general population matched on age, gender, calendar year at diagnosis and country, was calculated. Excess mortality rate ratios (EMRRs)
were also estimated to assess the effect of age, sex and time from MF diagnosis to start of ruxolitinib on excess mortality. Mortality data of the general population used for RS and EMRR estimates were obtained from the Human Mortality Database. 16 In addition, we investigated the loss in life expectancy (LEL) from ruxolitinib initiation and discontinuation using flexible parametric models adjusted for age, sex, calendar year and country. 17 LEL was calculated as the difference in life expectancy of MF patients from their index dates and that of the matched population. For the Swedish cohort, the number of patients receiving other MF-specific treatments as defined in the Nordic MPN recommendations 18 before, during and after ruxolitinib were summarised descriptively. Drugs dispensed before or on the date of the first ruxolitinib dispensation were considered treatment before ruxolitinib, and drugs dispensed after or on the date of the last ruxolitinib dispensation were considered treatment after ruxolitinib. Drugs dispensed between the first and the last ruxolitinib dispensation dates were considered dispensed during ruxolitinib treatment. RS and EMRRs were estimated using the relsurv package in R. LEL analyses were conducted using stpm2 package in STATA. Table 2 ). Among patients who discontinued ruxolitinib (n = 71), median RS from treatment discontinuation was 16.0 months (95% CI: 6.3, NE) ( Figure 2B ). From ruxolitinib treatment, discontinuation none of the studied variables in the EMRR model were significantly associated with excess mortality ( Table 2 ). The average MF-related LEL from ruxolitinib initiation was 11 years, and the corresponding LEL from ruxolitinib discontinuation was 12 years.
| RE SULTS
For the Swedish patients (n = 101), hydroxyurea (n = 73) was the most commonly used treatment before ruxolitinib initiation, followed by glucocorticoids (n = 53) and peginterferon alfa-2a (n = 17). During ruxolitinib treatment, glucocorticoids (n = 27) was frequently added and some patients also received hydroxyurea (n = 12). After ruxolitinib discontinuation (n = 37), a proportion of patients received glucocorticoids (n = 24), hydroxyurea (n = 12) and busulfan (n = 3) ( Table 3 ).
| D ISCUSS I ON
In the present study, Swedish and Norwegian registries were used to estimate survival in MF patients treated with ruxolitinib in clinical practice. The study demonstrates poor RS compared with a matched general population and emphasizes the lack of effective salvage treatment options after ruxolitinib discontinuation.
Follow-up studies of the COMFORT-I and COMFORT-II trials showed that half of the patients discontinued ruxolitinib within 3 years and another 25% discontinued within 5 years from ruxolitinib initiation. In controlled clinical trial settings, the most frequently reported causes of treatment discontinuation were disease progression, adverse events and lack of efficacy. 7 These findings were also supported by Kuykendall Previous studies have reported that allo-SCT, lenalidomide, thalidomide, interferon, danazol and hydroxyurea are frequently used after ruxolitinib discontinuation. 9, [17] [18] [19] In the present study, the most commonly used drugs were glucocorticoids (65.9%) followed by hydroxyurea (32.4%). The lack of effective treatment options is likely to contribute to high mortality rates.
The main strength of this study was the quality of data, that is index date is set to ruxolitinib initiation and discontinuation, and not MF diagnosis, the risk for immortal time bias is minimised. This assumption was also confirmed by the EMRR analyses since there was no statistical association with death when comparing patients with MF diagnosis less or more than 1 year from ruxolitinib initiation.
Results from the present study may be generalizable to corresponding patient populations in countries that have a healthcare system and treatment guidelines comparable to that in Sweden and Norway. This is the first real-world study using nationwide populationbased data to describe survival outcomes in MF patients who received ruxolitinib. The study results corroborate previous findings in similar patient populations and show that patients who discontinued ruxolitinib treatment had poor survival outcomes. Treatment options after ruxolitinib discontinuation were scarce and mostly limited to palliative care, highlighting the need for more effective therapeutic options.
